Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays

被引:210
作者
Hudson, Michael E.
Pozdnyakova, Irina
Haines, Kenneth
Mor, Gil
Snyder, Michael
机构
[1] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA
[2] Yale Univ, Dept Surg Pathol, New Haven, CT 06520 USA
[3] Yale Univ, Dept Obstet, New Haven, CT 06520 USA
[4] Yale Univ, Dept Gynecol, New Haven, CT 06520 USA
[5] Yale Univ, Dept Reprod Sci, New Haven, CT 06520 USA
[6] Yale Univ, Dept Biochem & Biophys, New Haven, CT 06520 USA
关键词
autoantibodies; tissue microarray; tissue marker; differential expression; cancer antigen;
D O I
10.1073/pnas.0708572104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Ovarian cancer is a leading cause of deaths, yet many aspects of the biology of the disease and a routine means of its detection are lacking. We have used protein microarrays and autoantibodies from cancer patients to identify proteins that are aberrantly expressed in ovarian tissue. Sera from 30 cancer patients and 30 healthy individuals were used to probe microarrays containing 5,005 human proteins. Ninety-four antigens were identified that exhibited enhanced reactivity from sera in cancer patients relative to control sera. The differential reactivity of four antigens was tested by using immunoblot analysis and tissue microarrays. Lamin A/C, SSRP1, and RALBP1 were found to exhibit increased expression in the cancer tissue relative to controls. The combined signals from multiple antigens proved to be a robust test to identify cancerous ovarian tissue. These antigens were also reactive with tissue from other types of cancer and thus are not specific to ovarian cancer. Overall our studies identified candidate tissue marker proteins for ovarian cancer and demonstrate that protein microarrays provide a powerful approach to identify proteins aberrantly expressed in disease states.
引用
收藏
页码:17494 / 17499
页数:6
相关论文
共 28 条
[21]   Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin [J].
Singhal, SS ;
Yadav, S ;
Singhal, J ;
Zajac, E ;
Awasthi, YC ;
Awasthi, S .
BIOCHEMICAL PHARMACOLOGY, 2005, 70 (03) :481-488
[22]   Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions [J].
Skates, SJ ;
Horick, N ;
Yu, YH ;
Xu, FJ ;
Berchuck, A ;
Havrilesky, LJ ;
de Bruijn, HWA ;
van der Zee, AGJ ;
Woolas, RP ;
Jacobs, IJ ;
Zhang, Z ;
Bast, RC .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (20) :4059-4066
[23]  
Soussi T, 2000, CANCER RES, V60, P1777
[24]   Serologic analysis of ovarian tumor antigens reveals a bias toward antigens encoded on 17q [J].
Stone, B ;
Schummer, M ;
Paley, PJ ;
Thompson, L ;
Stewart, J ;
Ford, M ;
Crawford, M ;
Urban, N ;
O'Briant, K ;
Nelson, BH .
INTERNATIONAL JOURNAL OF CANCER, 2003, 104 (01) :73-84
[25]   Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: A strategy for identification of candidate cancer biomarkers [J].
Wang, HX ;
Kachman, MT ;
Schwartz, DR ;
Cho, KR ;
Lubman, DM .
PROTEOMICS, 2004, 4 (08) :2476-2495
[26]   Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer [J].
Welsh, JB ;
Zarrinkar, PP ;
Sapinoso, LM ;
Kern, SG ;
Behling, CA ;
Monk, BJ ;
Lockhart, DJ ;
Burger, RA ;
Hampton, GM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (03) :1176-1181
[27]   Interaction of FACT, SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged by the anticancer drug cisplatin [J].
Yarnell, AT ;
Oh, S ;
Reinberg, D ;
Lippard, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (28) :25736-25741
[28]   ProCAT: a data analysis approach for protein microarrays [J].
Zhu, Xiaowei ;
Gerstein, Mark ;
Snyder, Michael .
GENOME BIOLOGY, 2006, 7 (11)